Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2012 (2012), Article ID 368536, 4 pages
http://dx.doi.org/10.1155/2012/368536
Research Article

Determinants of Extraocular Muscle Volume in Patients with Graves' Disease

1Specialized Diabetes and Endocrine Centre, King Fahad Medical City, Dabab Street, P.O. Box 59046, Riyadh 11525, Saudi Arabia
2Department of Medicine, Nepean Clinical School, Nepean Hospital, The University of Sydney, Derby Street, P.O. Box 63, Penrith 2751, New South Wales, Australia

Received 26 September 2011; Accepted 30 November 2011

Academic Editor: Leonidas H. Duntas

Copyright © 2012 Samer El-Kaissi and Jack R. Wall. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Villadolid, N. Yokoyama, M. Izumi et al., “Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance,” The Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 9, pp. 2830–2833, 1995. View at Google Scholar · View at Scopus
  2. E. A. Otto, K. Ochs, C. Hansen, J. R. Wall, and G. J. Kahaly, “Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens,” The Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 8, pp. 3045–3050, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Wall, N. Bernard, A. Boucher et al., “Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis,” Clinical Immunology and Immunopathology, vol. 68, no. 1, pp. 1–8, 1993. View at Publisher · View at Google Scholar
  4. J. R. Wall, I. Stachura, and J. H. Kennerdell, “Mitochondrial abnormalities in eye muscle fiber from three cases of thyroid-associated ophthalmopathy,” Thyroid, vol. 16, no. 11, pp. 1181–1183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. E. Busuttil and A. G. Frauman, “Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2315–2319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Hiromatsu, M. Sato, Y. Inoue et al., “Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy,” Thyroid, vol. 6, no. 6, pp. 553–562, 1996. View at Google Scholar · View at Scopus
  7. R. S. Bahn, “Clinical review 157—pathophysiology of Graves' ophthalmopathy: the cycle of disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 1939–1946, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. S. J. Kloprogge, B. E. Busuttil, and A. G. Frauman, “TSH receptor protein is selectively expressed in normal human extraocular muscle,” Muscle and Nerve, vol. 32, no. 1, pp. 95–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. El-Kaissi, J. Bowden, M. J. Henry et al., “Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy,” International Ophthalmology, vol. 30, no. 4, pp. 397–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Pinchera, W. Wiersinga, D. Glinoer et al., “Classification of eye changes of Graves' disease,” Thyroid, vol. 2, pp. 235–236, 1992. View at Google Scholar
  11. M. F. Prummel, A. Bakker, W. M. Wiersinga et al., “Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience,” European Journal of Endocrinology, vol. 148, no. 5, pp. 491–495, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. H. B. Burch and L. Wartofsky, “Graves' ophthalmopathy: current concepts regarding pathogenesis and management,” Endocrine Reviews, vol. 14, no. 6, pp. 747–793, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Tallstedt, G. Lundell, O. Torring et al., “Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism,” The New England Journal of Medicine, vol. 326, no. 26, pp. 1733–1738, 1992. View at Google Scholar
  14. R. D. Hamilton, W. E. Mayberry, W. M. McConahey, and K. C. Hanson, “Ophthalmopathy of Graves' disease: a comparison between patients treated surgically and patients treated with radioiodide,” Mayo Clinic Proceedings, vol. 42, no. 12, pp. 812–818, 1967. View at Google Scholar · View at Scopus
  15. F. A. Karlsson, P. A. Dahlberg, R. Jansson, K. Westermark, and P. Enoksson, “Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy,” Acta Endocrinologica, Supplement, vol. 121, no. 2, pp. 132–141, 1989. View at Google Scholar
  16. A. W. C. Kung, C. C. Yau, and A. Cheng, “The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole,” The Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 542–546, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Tallstedt, G. Lundell, H. Blomgren, and J. Bring, “Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?” European Journal of Endocrinology, vol. 130, no. 5, pp. 494–497, 1994. View at Google Scholar · View at Scopus
  18. L. M. Demers and C. A. Spencer, “Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease,” Clinical Endocrinology, vol. 58, no. 2, pp. 138–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. El-Kaissi, A. G. Frauman, and J. R. Wall, “Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management,” Internal Medicine Journal, vol. 34, no. 8, pp. 482–491, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Lahooti, K. R. Parmar, and J. R. Wall, “Pathogenesis of thyroid-associated Ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role?” Clinical Ophthalmology, vol. 4, no. 1, pp. 417–425, 2010. View at Google Scholar · View at Scopus
  21. D. H. C. Khoo, S. C. Ho, L. L. Seah et al., “The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves disease identifies a group at markedly increased risk of ophthalmopathy,” Thyroid, vol. 9, no. 12, pp. 1175–1180, 1999. View at Google Scholar · View at Scopus
  22. A. K. Eckstein, M. Plicht, H. Lax et al., “Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3464–3470, 2006. View at Publisher · View at Google Scholar
  23. M. N. Gerding, J. W. C. Van Der Meer, M. Broenink, O. Bakker, W. M. Wiersinga, and M. F. Prummel, “Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy,” Clinical Endocrinology, vol. 52, no. 3, pp. 267–271, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. W. M. Wiersinga, P. Perros, G. J. Kahaly et al., “Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' orbitopathy recommendations to generalists, specialists and clinical researchers,” European Journal of Endocrinology, vol. 155, no. 3, pp. 387–389, 2006. View at Publisher · View at Google Scholar · View at Scopus